L-methylfolate,
does it really help with Improvement in depression and adjunctive antidepressant therapy?
research showsRandomized trials and meta-analysis of L-methylfolate 15 mg/day added to treatment in major depressive disorder with inadequate SSRI response support a small but significant improvement in symptoms and response, resulting in B for adjunctive therapy. However, key trials are concentrated in a Pamlab-supported program, the effect is modest, and neither mood enhancement in the general population nor a need for high-dose treatment based on an MTHFR variant alone has been established.
ads claimMarketing uses terms such as 'active folate,' 'brain methylation,' and 'MTHFR personalized' to connect a common MTHFR variant with a need for 15 mg or to claim better mood and energy in healthy people. Established positive evidence is concentrated in adjunctive treatment for major depressive disorder with inadequate antidepressant response.
Useful facts when choosing a product
- In South Korea, 5-MTHF products containing roughly 0.4-1 mg are sold alongside imported high-dose 15 mg products, distinct from ordinary folic-acid supplements.
- The positive depression RCT dose was L-methylfolate 15 mg/day, while the first trial centered on 7.5 mg did not show superiority.
- Fifteen milligrams is dozens of times higher than the hundreds of micrograms used in general nutritional supplements, and deficiency correction is a different evidence question from antidepressant augmentation.
- Overall tolerability in trials was similar to placebo, while high-dose folate compounds raise separate safety questions involving delayed recognition of vitamin B12 deficiency, drug interactions, and rare activation or mania reports.
What the research actually shows
Papakostas and colleagues enrolled outpatients with major depressive disorder and inadequate SSRI response in two 60-day sequential-parallel trials. The first trial with 148 participants did not show superiority for the strategy centered on 7.5 mg, while the second trial with 75 participants found significant effects of 15 mg/day on both primary outcomes, response rate and change in depression symptoms. Al Maruf 2022 qualitatively reviewed nine articles with 6,707 patients and found a response relative risk of 1.25 across three meta-analyzable studies with 483 patients and a continuous-symptom standardized mean difference of -0.38 across four studies with 507 patients, describing the efficacy as modest. A 2014 biomarker and genotype paper was a post hoc analysis of the same 15 mg trial, not an independent MTHFR-selected RCT.
Why this is classified as B (66)
A positive randomized trial and meta-analysis support B for 15 mg augmentation in major depressive disorder with inadequate SSRI response. However, key trials are concentrated in one development program with Pamlab support, samples and duration are limited, and the pooled effect is modest, limiting the score to B with 66 points. Direct trials of general-population mood enhancement are absent, resulting in unknown, while high-dose need based solely on an MTHFR variant rests on post hoc biomarker work and is C.
Counterpoint. The response-rate and symptom signal for adding 15 mg in adults with partial or no antidepressant response persists in meta-analysis. It does not establish antidepressant replacement or mood enhancement in healthy people.
Rejudgment record. New verdict — A 15 mg augmentation RCT and meta-analysis are positive in major depressive disorder with inadequate SSRI response, but the 7.5 mg trial was null and Pamlab funding concentration, modest effects, and limited independent replication cap the grade at B
Sub-claim grades by effect
This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.
| Effect (sub-claim) | Grade | Basis |
|---|---|---|
| Adjunctive 15 mg therapy for major depressive disorder with inadequate SSRI response | B | A positive RCT and meta-analysis exist, but Pamlab funding concentration and modest effects remain. |
| Mood enhancement in people without depression | ? | No robust human trial directly testing mood enhancement in this population was identified. |
| A presumed need for 15 mg based on an MTHFR variant alone | C | Evidence is limited to a post hoc biomarker and genotype analysis of the same RCT, without an independent genotype-selected trial. |
Cross-check — Codex and Claude
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| Papakostas GI et al. 2012 | Two multicenter randomized double-blind sequential-parallel placebo-controlled trials | 75 | Pamlab-supported development program | Depression response rate and change in HDRS symptoms | The first trial centered on 7.5 mg was null; the second 15 mg trial was positive on both primary outcomes and selected secondary outcomes. | Key, industry-linked |
| Al Maruf A et al. 2022 | Systematic review and meta-analysis | 507 | Academic institutions; one author disclosed employment by a genetic-testing company | Antidepressant response rate and change in depressive symptoms | A modest adjunctive effect was reported, with response RR 1.25 and continuous-symptom SMD -0.38. | Key synthesis |
| Papakostas GI et al. 2014 | Post hoc biomarker and genotype analysis of the 15 mg RCT | Supported by Pamlab | HDRS response stratified by inflammatory, metabolic, and genetic markers | Selected marker combinations showed a larger response signal, but the analysis was exploratory and post hoc. | Subclaim, exploratory |
Receipt — 4 References
All 4 cited sources were verified for existence at the original page (as of 2026-07-16).
Reviewed and approved: Chamgap Editorial Team · Approval date: 2026-07-16 · Corrections: none
Cite this verdict
[Chamgap] L-methylfolate (5-MTHF) x improvement in depression and adjunctive antidepressant therapy — Evidence Grade B·66. 4 cited sources checked. Source: https://chamgap.com/en/verdicts/mood/l-methylfolate-depression-adjunct/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.